The objective is to describe the epidemiological, clinical and therapeutic aspects of retinal damage in sickle cell disease. This was a cross-sectional, descriptive and analytical study, conducted from November 2022 to February 2023, i. e. for a period of 4 months in a private ophthalmology centre in Abidjan and at the University Hospital of Cocody (Côte d'Ivoire). It focused on sickle cell patients seen in consultation. A total of 50 patients, i. e. 100 eyes were included, corresponding to the sample. The data were entered and analysed using SPSS software. The mean age of the patients was 30 years ±10.495. Sickle cell disease SC was the most frequent form (52%). Half of the eyes (50%) had retinal damage with 34% of proliferative retinopathy (34 eyes). The most common Goldberg angiographic stage was stage III (73.53%). Laser photocoagulation was performed in stage III eyes. Retinal damage in sickle cell disease is common and is most often seen in SC patients. Stage III neovascularisation is the barrier that must not be crossed, as the consequences are dramatic with irreversible blindness. Laser photocoagulation is necessary to prevent the formation or to promote the regression of neovessels. Screening should be annual and especially with fluorescein retinal angiography.
| Published in | European Journal of Preventive Medicine (Volume 11, Issue 4) |
| DOI | 10.11648/j.ejpm.20231104.12 |
| Page(s) | 48-52 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Retinal Neovascularisation, Sickle Cell, Epidemiology
| [1] | Beutler E, Lichtman M, Coller B, Kipps T. Hemoglobinopathies associated with unstable hemoglobin. Williams’ Hematol N Y McGraw Hill. 1995; 650-4. |
| [2] | Kakou-Danho B, Atiméré YN, Koné D, Akroman M, Boka A, Diakité L. Prévalence des hémoglobinopathies au laboratoire central du CHU de Treichville à Abidjan. Rev int sc méd Abj. 2020; 22, 3: 210-215. |
| [3] | Bonanomi MTBC, Lavezzo MM. Sickle cell retinopathy: diagnosis and treatment. Arq Bras Oftalmol. oct 2013; 76: 320-7. |
| [4] | Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010; 85 (1): 6-13. |
| [5] | Dembélé AK, Toure BA, Sarro YS, Guindo A, Fané B, Offredo L, et al. Prévalence et facteurs de risque de la rétinopathie drépanocytaire dans un centre de suivi drépanocytaire d’Afrique subsaharienne. Rev Médecine Interne. 1 sept 2017; 38 (9): 572-7. |
| [6] | Leveziel N, Lalloum F, Bastuji-Garin S, Binaghi M, Bachir D, Galacteros F, et al. Rétinopathie drépanocytaire: analyse rétrospective portant sur 730 patients suivis dans un centre de référence. J Fr Ophtalmol. 1 mai 2012; 35 (5): 343-7. |
| [7] | Fanny A, Coulibaly F, Gbe K, Meite M, Adjorlolo C, Konan-Toure ML, et al. Les bêtathalasso-drépanocytoses pourvoyeuses de rétinopathies ischémiques graves: À propos de 18 patients étudiés à Abidjan. J Fr Ophtalmol. 2005; 28 (4): 391-5. |
| [8] | Goldberg MF. Classification and pathogenesis of proliferative sickle retinopathy. Am J Ophthalmol. 1971; 71 (3): 649-65. |
| [9] | Odoulami-Yehouessi L, Hounnou-Tchabi S, Anani L, Sounouvou I, Sagbohan V, Dehoumon J, et al. La rétinopathie drépanocytaire au CNHU-HKM de Cotonou: à propos de 53 cas. Rev CAMES. 2009; 08 (Serie A): 28-31. |
| [10] | Fany A, Boni S, Adjorlolo C, Konan MT, Gbe K, Coulibaly F, et al. La rétinopathie chez le porteur du trait drépanocytaire AS: mythe ou réalité? J Fr Ophtalmol. 2004; 27 (9): 1025-30. |
| [11] | Conaré I, Sidibé M, Napo A, Guirou N, Guindo A, Bakayoko S, et al. Prise En Charge De La Retinopathie Drepanocytaire: A Propos De 119 Cas Au Chu-Iota. Rev SOAO-N. 2018; 38-42. |
| [12] | Akinsola F, Kehinde M. Ocular findings in sickle cell disease patients in Lagos. Niger Postgrad Med J. 2004; 11 (3): 203-6. |
| [13] | Binaghi M, Levy C., 1993. Œil et hémoglobinopathies. Encyclopédie Médico-Chirurgicale. Ophtalmologie, 21- 452-G-20.7p. |
| [14] | Balo KP, Segbena K, Mensah A, Mihluedo H, Bechetoille A. Hemoglobinopathies and retinopathies in Lomé UHC. J Fr Ophtalmol. 1996; 19 (8-9): 497-504. |
| [15] | Diallo J, Sanfo O, Blot I, Meda N, Sawadogo P, Ouedraogo A, et al. Étude épidémiologique et facteurs pronostiques de la rétinopathie drépanocytaire à Ouagadougou (Burkina Faso). J Fr Ophtalmol. 2009; 32 (7): 496-500. |
APA Style
Koman Chiatse Ellalie, Kouassi Colette Rebours, Agbohoun Reine Prisca, N’da Hermine Cynthia, Konan Manmi Sienou Marguerite Pascaline, et al. (2023). Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast). European Journal of Preventive Medicine, 11(4), 48-52. https://doi.org/10.11648/j.ejpm.20231104.12
ACS Style
Koman Chiatse Ellalie; Kouassi Colette Rebours; Agbohoun Reine Prisca; N’da Hermine Cynthia; Konan Manmi Sienou Marguerite Pascaline, et al. Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast). Eur. J. Prev. Med. 2023, 11(4), 48-52. doi: 10.11648/j.ejpm.20231104.12
AMA Style
Koman Chiatse Ellalie, Kouassi Colette Rebours, Agbohoun Reine Prisca, N’da Hermine Cynthia, Konan Manmi Sienou Marguerite Pascaline, et al. Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast). Eur J Prev Med. 2023;11(4):48-52. doi: 10.11648/j.ejpm.20231104.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ejpm.20231104.12,
author = {Koman Chiatse Ellalie and Kouassi Colette Rebours and Agbohoun Reine Prisca and N’da Hermine Cynthia and Konan Manmi Sienou Marguerite Pascaline and Kra Allah N’goran Simeon and Poualeu Siewen Franck Loique and Soumahoro Massesse and Kouassi Francois Xavier},
title = {Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast)},
journal = {European Journal of Preventive Medicine},
volume = {11},
number = {4},
pages = {48-52},
doi = {10.11648/j.ejpm.20231104.12},
url = {https://doi.org/10.11648/j.ejpm.20231104.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejpm.20231104.12},
abstract = {The objective is to describe the epidemiological, clinical and therapeutic aspects of retinal damage in sickle cell disease. This was a cross-sectional, descriptive and analytical study, conducted from November 2022 to February 2023, i. e. for a period of 4 months in a private ophthalmology centre in Abidjan and at the University Hospital of Cocody (Côte d'Ivoire). It focused on sickle cell patients seen in consultation. A total of 50 patients, i. e. 100 eyes were included, corresponding to the sample. The data were entered and analysed using SPSS software. The mean age of the patients was 30 years ±10.495. Sickle cell disease SC was the most frequent form (52%). Half of the eyes (50%) had retinal damage with 34% of proliferative retinopathy (34 eyes). The most common Goldberg angiographic stage was stage III (73.53%). Laser photocoagulation was performed in stage III eyes. Retinal damage in sickle cell disease is common and is most often seen in SC patients. Stage III neovascularisation is the barrier that must not be crossed, as the consequences are dramatic with irreversible blindness. Laser photocoagulation is necessary to prevent the formation or to promote the regression of neovessels. Screening should be annual and especially with fluorescein retinal angiography.},
year = {2023}
}
TY - JOUR T1 - Retinal Damage in Sickle Cell Disease in Abidjan (Ivory Coast) AU - Koman Chiatse Ellalie AU - Kouassi Colette Rebours AU - Agbohoun Reine Prisca AU - N’da Hermine Cynthia AU - Konan Manmi Sienou Marguerite Pascaline AU - Kra Allah N’goran Simeon AU - Poualeu Siewen Franck Loique AU - Soumahoro Massesse AU - Kouassi Francois Xavier Y1 - 2023/07/11 PY - 2023 N1 - https://doi.org/10.11648/j.ejpm.20231104.12 DO - 10.11648/j.ejpm.20231104.12 T2 - European Journal of Preventive Medicine JF - European Journal of Preventive Medicine JO - European Journal of Preventive Medicine SP - 48 EP - 52 PB - Science Publishing Group SN - 2330-8230 UR - https://doi.org/10.11648/j.ejpm.20231104.12 AB - The objective is to describe the epidemiological, clinical and therapeutic aspects of retinal damage in sickle cell disease. This was a cross-sectional, descriptive and analytical study, conducted from November 2022 to February 2023, i. e. for a period of 4 months in a private ophthalmology centre in Abidjan and at the University Hospital of Cocody (Côte d'Ivoire). It focused on sickle cell patients seen in consultation. A total of 50 patients, i. e. 100 eyes were included, corresponding to the sample. The data were entered and analysed using SPSS software. The mean age of the patients was 30 years ±10.495. Sickle cell disease SC was the most frequent form (52%). Half of the eyes (50%) had retinal damage with 34% of proliferative retinopathy (34 eyes). The most common Goldberg angiographic stage was stage III (73.53%). Laser photocoagulation was performed in stage III eyes. Retinal damage in sickle cell disease is common and is most often seen in SC patients. Stage III neovascularisation is the barrier that must not be crossed, as the consequences are dramatic with irreversible blindness. Laser photocoagulation is necessary to prevent the formation or to promote the regression of neovessels. Screening should be annual and especially with fluorescein retinal angiography. VL - 11 IS - 4 ER -
Email: